A phase I study of intravenous aflibercept with FOLFIRI in Japanese patients with previously treated metastatic colorectal cancer

Aflibercept, a recombinant fusion protein, is a potent inhibitor of vascular endothelial growth factor (VEGF)-A, VEGF-B, and the placental growth factor (PlGF). The present study was an open-label, sequential-cohort, dose-escalation trial of intravenous aflibercept administered every 2 weeks in comb...

Descripción completa

Detalles Bibliográficos
Autores principales: Yoshino, Takayuki, Yamazaki, Kentaro, Yamaguchi, Kensei, Doi, Toshihiko, Boku, Narikazu, Machida, Nozomu, Onozawa, Yusuke, Asayama, Masako, Fujino, Tadahiro, Ohtsu, Atsushi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2012
Materias:
Phase I Studies
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3717157/
https://www.ncbi.nlm.nih.gov/pubmed/23179335
http://dx.doi.org/10.1007/s10637-012-9895-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3717157/
https://www.ncbi.nlm.nih.gov/pubmed/23179335
http://dx.doi.org/10.1007/s10637-012-9895-6

Ejemplares similares